AbbVie to Strengthen Neuroscience Pipeline with $8.7 Billion for Cerevel Therapeutics

AbbVie and Cerevel Therapeutics announced that AbbVie will buy Cerevel Therapeutics and its neuroscience pipeline of schizophrenia, Parkinson's disease, and mood disorder drugs that are in multiple clinical and preclinical…

Continue ReadingAbbVie to Strengthen Neuroscience Pipeline with $8.7 Billion for Cerevel Therapeutics